The drug is the only immuno-oncology drug approved by various regulatory authorities around the world for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), an aggressive form of head and neck cancer that originates in the upper part of the throat
The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.
Hyderabad: A team of researchers from the School of Life Sciences, University of Hyderabad and Dr.Reddy’s Institute of Life Sciences have validated the 12R-LOX enzyme as the target for development of anti-psoriasis drugs. According to an official note from the University of Hyderabad, a recognized feature of psoriasis and other proliferative dermatoses (skin defects) was […]
